GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Beneish M-Score

INVO Bioscience (INVO Bioscience) Beneish M-Score : 0.04 (As of Jun. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.04 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for INVO Bioscience's Beneish M-Score or its related term are showing as below:

INVO' s Beneish M-Score Range Over the Past 10 Years
Min: -43.2   Med: -2.99   Max: 123.51
Current: 0.04

During the past 13 years, the highest Beneish M-Score of INVO Bioscience was 123.51. The lowest was -43.20. And the median was -2.99.


INVO Bioscience Beneish M-Score Historical Data

The historical data trend for INVO Bioscience's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Beneish M-Score Chart

INVO Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.08 -1.84 2.87 1.64 -0.88

INVO Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 -1.95 -0.28 -0.88 0.04

Competitive Comparison of INVO Bioscience's Beneish M-Score

For the Medical Devices subindustry, INVO Bioscience's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


INVO Bioscience's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, INVO Bioscience's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where INVO Bioscience's Beneish M-Score falls into.



INVO Bioscience Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of INVO Bioscience for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4195+0.528 * 0.2544+0.404 * 3.6676+0.892 * 4.2195+0.115 * 0.1119
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1602+4.679 * -0.134403-0.327 * 0.7373
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $0.18 Mil.
Revenue was 1.576 + 1.382 + 0.975 + 0.316 = $4.25 Mil.
Gross Profit was 0.726 + 0.495 + 0.394 + 0.06 = $1.68 Mil.
Total Current Assets was $1.73 Mil.
Total Assets was $18.32 Mil.
Property, Plant and Equipment(Net PPE) was $3.78 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.41 Mil.
Selling, General, & Admin. Expense(SGA) was $6.60 Mil.
Total Current Liabilities was $8.96 Mil.
Long-Term Debt & Capital Lease Obligation was $4.35 Mil.
Net Income was -1.597 + -1.995 + -1.248 + -2.241 = $-7.08 Mil.
Non Operating Income was -0.467 + -0.281 + -0.008 + 0.004 = $-0.75 Mil.
Cash Flow from Operations was -0.261 + -0.715 + -1.247 + -1.644 = $-3.87 Mil.
Total Receivables was $0.10 Mil.
Revenue was 0.348 + 0.278 + 0.235 + 0.146 = $1.01 Mil.
Gross Profit was 0.117 + 0.044 + -0.014 + -0.046 = $0.10 Mil.
Total Current Assets was $2.81 Mil.
Total Assets was $6.15 Mil.
Property, Plant and Equipment(Net PPE) was $2.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $9.76 Mil.
Total Current Liabilities was $4.45 Mil.
Long-Term Debt & Capital Lease Obligation was $1.61 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.177 / 4.249) / (0.1 / 1.007)
=0.041657 / 0.099305
=0.4195

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.101 / 1.007) / (1.675 / 4.249)
=0.100298 / 0.39421
=0.2544

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1.725 + 3.781) / 18.318) / (1 - (2.81 + 2.168) / 6.151)
=0.699421 / 0.190701
=3.6676

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4.249 / 1.007
=4.2195

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.024 / (0.024 + 2.168)) / (0.41 / (0.41 + 3.781))
=0.010949 / 0.097829
=0.1119

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6.597 / 4.249) / (9.761 / 1.007)
=1.552601 / 9.693148
=0.1602

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.352 + 8.956) / 18.318) / ((1.611 + 4.45) / 6.151)
=0.726499 / 0.985368
=0.7373

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-7.081 - -0.752 - -3.867) / 18.318
=-0.134403

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

INVO Bioscience has a M-score of 0.04 signals that the company is likely to be a manipulator.


INVO Bioscience Beneish M-Score Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


INVO Bioscience (INVO Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880